Sanofi Pasteur is the vaccine division of Sanofi, a multinational pharmaceutical company based in France. With its headquarters located in Lyon, France, Sanofi Pasteur has been at the forefront of researching, developing, and producing vaccines to protect people from various infectious diseases for more than a century. The origins of Sanofi Pasteur date back to 1897 when Marcel Mérieux founded the Mérieux Biological Institute in Lyon.

Over the years, the institute grew into a leading global player in the field of vaccines. In 1974, the company merged with Rhône-Poulenc to become Rhone-Poulenc Rorer. Eventually, in 1999, it merged with Hoechst AG to form today's Sanofi-Aventis, which later rebranded as Sanofi.

Sanofi Pasteur's headquarters in Lyon is a hub for research and development, manufacturing, and commercial operations. The company operates in over 170 countries and is dedicated to preventing diseases through innovative vaccine solutions. It offers a wide range of vaccines for various diseases, including influenza, meningitis, travel-related infections, and pediatric diseases such as diphtheria, tetanus, and pertussis.

Sanofi Pasteur collaborates with numerous partners around the world. It has made several noteworthy partnerships and acquisitions to enhance its portfolio and expand its global reach. Notable subsidiaries and ventures include Vaxserve, Acambis, and Immune Design.

The company has also entered into partnerships with organizations like GSK, BARDA, and Translate Bio to develop and produce vaccines. As of 2020, Sanofi Pasteur maintains a strong market position globally. It generates significant revenue through its vaccine sales, contributing to Sanofi's overall success.

With a focus on innovation, the company continually strives to improve existing vaccines and develop new ones to address emerging healthcare challenges. The COVID-19 pandemic brought significant attention to Sanofi Pasteur, leading the company to participate in the development of a vaccine against the virus. In collaboration with GlaxoSmithKline (GSK), Sanofi Pasteur is working to develop an adjuvanted vaccine candidate against COVID-19, leveraging GSK's pandemic adjuvant technology.

As of the latest information available, Sanofi Pasteur continues to be a leading player in the global vaccine industry, committed to improving global health through its research, development, and production of innovative vaccines for the prevention of infectious diseases